• 22 March 2018

    Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the appointment of Caroline Van Hove as the Company’s first Chief Commercial Officer. Ms. Van Hove will develop, lead and have overall responsibility for Sienna’s commercial strategy and operations. Sienna currently has five clinical-stage programs in development from the Company’s Topical by Design™ and Topical Photoparticle Therapy™ platforms.

  • 22 March 2018

    TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory ocular and gastrointestinal diseases, today announces the publication of “Narrow Spectrum Kinase Inhibitors Demonstrate Promise for the Treatment of Dry Eye Disease and Other Ocular Inflammatory Disorders” in Investigative Ophthalmology & Visual Science (IOVS, March 2018, Vol. 59, 1443–1453), a peer-reviewed journal for the dissemination of results from laboratory and clinical ophthalmic and vision research. 

  • 21 March 2018

    Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the appointment of John W. Smither as the Company’s Chief Financial Officer. Mr. Smither will succeed Richard Peterson, who has resigned for personal reasons, effective Mar. 29, 2018.

  • 20 March 2018

    Sequana Medical AG (“Sequana Medical”), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of a multicentre, randomized controlled study in Quality of Life Research (

  • 14 March 2018

    Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that the United States Patent and Trademark Office ("USPTO") issued U.S. Patent No. 9914767 to the company. This patent broadly claims composition of matter for antibodies that cross-neutralize Staphylococcus aureusalpha hemolysin (Hla) and up to four additional S. aureus leukocidins targeted by ASN-1, one of the two antibodies in the company’s lead product candidate, ASN100. ASN100 is a combination of two fully human monoclonal antibodies (mAbs) that together neutralize the six cytotoxins critical to S. aureus pneumonia pathogenesis, including toxins that damage lung tissue and destroy human immune cells. This patent grants intellectual property protection in the United Statesthrough 2033.